Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2U45Q)

Drug Name
Danegaptide Drug Info
Synonyms SCHEMBL2399760; BCP17534; ZP 1609
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Phase 2 [1]
Cross-matching ID
PubChem CID
16656685
CAS Number
CAS 943134-39-2
TTD Drug ID
DM2U45Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Gap junction protein (GJP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ROTIGAPTIDE DMXB9RS Cardiac arrhythmias BC9Z Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gap junction protein (GJP) TTJO6E9 NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT01977755) Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health.
2 The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33.
3 The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95.